Alignment Healthcare (ALHC) Expected to Announce Earnings on Thursday

Alignment Healthcare (NASDAQ:ALHC - Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data after the market closes on Thursday, May 1st. Analysts expect the company to announce earnings of ($0.14) per share and revenue of $889.83 million for the quarter.

Alignment Healthcare Stock Performance

ALHC traded down $0.52 on Friday, hitting $17.52. 3,180,864 shares of the company's stock were exchanged, compared to its average volume of 1,718,993. The company has a current ratio of 1.60, a quick ratio of 1.60 and a debt-to-equity ratio of 1.82. The firm has a market cap of $3.36 billion, a PE ratio of -22.75 and a beta of 1.32. Alignment Healthcare has a twelve month low of $5.02 and a twelve month high of $21.06. The stock has a fifty day moving average of $16.94 and a two-hundred day moving average of $14.10.

Insider Transactions at Alignment Healthcare

In other Alignment Healthcare news, CEO John E. Kao sold 90,000 shares of the business's stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $14.23, for a total transaction of $1,280,700.00. Following the sale, the chief executive officer now owns 2,183,100 shares in the company, valued at approximately $31,065,513. The trade was a 3.96 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Andreas P. Wagner sold 14,878 shares of the company's stock in a transaction dated Wednesday, February 12th. The shares were sold at an average price of $14.38, for a total transaction of $213,945.64. Following the sale, the insider now directly owns 200,885 shares of the company's stock, valued at $2,888,726.30. This represents a 6.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 2,156,855 shares of company stock valued at $34,744,307 in the last quarter. Insiders own 6.60% of the company's stock.

Analyst Upgrades and Downgrades

ALHC has been the subject of several recent analyst reports. Bank of America upped their target price on shares of Alignment Healthcare from $15.50 to $18.50 and gave the stock a "buy" rating in a research report on Tuesday, March 4th. Barclays raised their target price on Alignment Healthcare from $8.00 to $9.00 and gave the company an "underweight" rating in a research report on Friday, February 28th. Robert W. Baird boosted their price target on Alignment Healthcare from $17.00 to $22.00 and gave the stock an "outperform" rating in a research report on Tuesday, April 15th. JPMorgan Chase & Co. raised their price target on Alignment Healthcare from $14.00 to $17.00 and gave the company a "neutral" rating in a report on Thursday, March 6th. Finally, William Blair reaffirmed an "outperform" rating on shares of Alignment Healthcare in a report on Friday, February 28th. One research analyst has rated the stock with a sell rating, three have given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Alignment Healthcare currently has a consensus rating of "Moderate Buy" and a consensus target price of $16.61.

About Alignment Healthcare

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.